At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 136 enrolled
Drug / intervention
mecamylamine +1 moredrug
Likely dose
mecamylamine 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
In Brief
A Phase 2 clinical trial evaluating mecamylamine and Placebo for Alcoholism. Completed, enrolled 136 participants across 1 site.
Detailed Summary
The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients. We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption than placebo. We further hypothesize that mecamylamine will be effective in reducing both alcohol consumption and smoking in a subset of alcoholics who also smoke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2004
First PostedJun 2006
Primary CompletionJul 2015
TodayJul 2026
First PostedJun 21, 2006
Enrollment StartMay 1, 2004
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11.2 yearsPosted 20.0 years ago
Interventions
mecamylaminedrug
mecamylamine 10mg/day
Placebodrug
Placebo